Omadacycline for treatment of acute bacterial infections: a meta-analysis of phase II/III trials.

BMC Infect Dis · 2023 · PMC10105466 · PMID 37059988

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In a meta-analysis reported, the risks of nausea (6.5%, 41/629) and vomiting (3.8%, 24/629) in the eravacycline group were higher than those in the comparator group, but these differences did not reach statistical significance (for nausea, RR = 4.79, 95% CI = 0.84–27.14, I 2 = 70%; for vomiting, RR = 1.46, 95% CI = 0.76–2.81; I 2 = 0%) [ 30 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.